Safety of Clofarabine With Multiagent Chemotherapy in Childhood Acute Lymphoblastic Leukemia
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine Maximum Tolerated Dosage (MTD), Dosage Limited
Toxicities (DLT), and the Rate Phase 2 Dosage of clofarabine when used in combination with
etoposide, asparaginase, mitoxantrone and dexamethasone and to assess the feasibility and
safety of this combination regimen to treat children with high risk relapsed or refractory
acute lymphoblastic leukemia (ALL).
Phase:
Phase 1
Details
Lead Sponsor:
University Hospital, Lille
Collaborators:
Assistance Publique - Hôpitaux de Paris Central Hospital, Nancy, France Centre Hospitalier Universitaire de Besancon Hospices Civils de Lyon Nantes University Hospital Rennes University Hospital Saint-Louis Hospital, Paris, France University Hospital, Bordeaux University Hospital, Marseille University Hospital, Toulouse